Taken together, our study with Nhe1 deletion in GAMs or pharmacological NHE1 blockade in conjunction with TMZ therapy modulates TME by reducing tumor-promoting tolerogenic GAMs. This evidence concerns the gene SLC9A1 and neoplasm.